Symrise announced a partnership with Swedish company Probi to develop probiotics-based cosmetic ingredients for skin care applications. This partnership looks to leverage Probi's expertise with clinically proven bacterial probiotic strains and Symrise's large-scale manufacturing capabilities. In another related development, DSM Venturing announced €4 million Series A funding in skin microbiome company S-Biomedic. The Belgian startup (Lux Take: Wait and See) develops skin therapeutics based on direct microbiome modulation, targeting acne vulgaris. As the gap between science and product development closes, we expect that the skin microbiome space will have a profound impact on future formulations in the beauty and personal care market.
For the original news article,